Lilly Aims To Have 30 NMEs In Clinic By 2009
This article was originally published in The Pink Sheet Daily
Executive Summary
Goal is to launch an average of two products per year by 2011 and three a year starting in 2014, CEO Taurel says.
You may also be interested in...
Alimta Beats Gemcitabine In Some NSCLC Types
But Phase III results show similar efficacy in patients overall.
Alimta Beats Gemcitabine In Some NSCLC Types
But Phase III results show similar efficacy in patients overall.
New Lilly Head Lechleiter Streamlines Operations
Exec, who assumed CEO role April 1, takes steps to eliminate "bureaucracy" in U.S., R&D units.